3,4-dimethyl-2-pyrone | 62968-83-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: 3,4-dimethyl-2-pyrone
• 英文别名: Dimethylpyron；3,4-dimethylpyran-2-one
• CAS: 62968-83-6
• 化学式: C₇H₈O₂
• 分子量: 124.139
• InChiKey: QMCKGKBSGKZPON-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,3-二甲基-4H-吡喃-4-酮 、 硫酸 生成 3,4-dimethyl-2-pyrone
  参考文献：
  名称：

  PAVLIK, J. W.;PATTEN, A. D.;BOLIN, D. R.;BRADFORD, K. C.;CLENNAN, E. L., J. ORG. CHEM., 1984, 49, N 23, 4523-4531

  摘要：

  DOI：

文献信息

• Oxime sulfonates and the use thereof as latent acids
  申请人：Yamato Hitoshi

  公开号：US20100167178A1

  公开（公告）日：2010-07-01

  Compounds of the formula (I), (II) or (III), wherein R 1 is for example C 1 -C 18 alkylsulfonyl, C 1 -C 10 haloalkylsulfonyl, camphorylsulfonyl, phenyl-C 1 -C 3 alkylsulfonyl, phenylsulfonyl, naphthylsulfonyl, anthrylsulfonyl, phenanthrylsulfonyl or heteroarylsulfonyl, R′ 1 is for example phenylenedisulfonyl, R 2 is for example CN, C 1 -C 10 haloalkyl or C 1 -C 10 haloalkyl which is substituted by (IV); Ar 1 is for example phenyl optionally substituted by a group of formula (IV); Ar′ 1 is for example phenylene which optionally is substituted by a group of formula (IV); A 1 , A 2 and A 3 independently of each other are for example hydrogen, halogen, CN, or C 1 -C 18 alkyl; D 2 is for example a direct bond, O, (CO)O, (CO)S, SO 2 , OSO 2 or C 1 -C 18 alkylene; or A 3 and D 2 together form C 3 -C 30 cycloalkenyl; or A 2 and D 2 together with the carbon of the ethylenically unsaturated double bond to which they are attached form C 3 -C 30 cycloalkyl; D 3 and D 4 for example independently of each other are a direct bond, O, S, C 1 -C 18 alkylene or C 3 -C 30 cycloalkylene provided that at least one of the radicals R 2 , Ar 1 or Ar′ 1 comprises a group of the formula (IV); are suitable as photolatent acid donors and for the preparation of corresponding polymers to be employed in chemically amplified photoresists.

  化合物的公式为（I），（II）或（III），其中R1例如为C1-C18烷基磺酰基，C1-C10卤代烷基磺酰基，樟脑磺酰基，苯基-C1-C3烷基磺酰基，苯基磺酰基，萘基磺酰基，蒽基磺酰基，菲磺酰基或杂环芳基磺酰基，R'1例如为苯基二磺酰基，R2例如为CN，C1-C10卤代烷基或被（IV）取代的C1-C10卤代烷基；Ar1例如为苯基，可选地被公式（IV）的基团取代；Ar'1例如为苯基，可选地被公式（IV）的基团取代；A1，A2和A3独立地例如为氢，卤素，CN或C1-C18烷基；D2例如为直接键，O，（CO）O，（CO）S，SO2，OSO2或C1-C18烷基；或A3和D2一起形成C3-C30环烯基；或A2和D2与它们所附着的乙烯基双键的碳一起形成C3-C30环烷基；D3和D4例如独立地为直接键，O，S，C1-C18烷基或C3-C30环烷基，至少其中之一的基团R2，Ar1或Ar'1包含公式（IV）的基团，适用作光激发酸给体，并用于制备相应的聚合物，以用于化学增强型光刻胶。
• [EN] SULFONIUM DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS<br/>[FR] DÉRIVÉS DE SULFONIUM ET LEUR UTILISATION COMME ACIDES LATENTS
  申请人：BASF SE

  公开号：WO2009150074A1

  公开（公告）日：2009-12-17

  Compounds of the formula (I), wherein R1, R2 and R3 for example are hydrogen, halogen, CN, C1-C18alkyl, C1-C10 haloalkyl, (CO)R8, (CO)OR4, or (CO)NR5R6; Y is O, S or CO; D2, D3 and D4 for example are a direct bond, O, S, NR7, CO, O(CO), (CO)O, S(CO), (CO)S, NR7(CO), (CO)NR7, SO, SO2, or OSO2, C1-C18alkylene, C3-C30cycloalkylene, C2-C12alkenylene, C4-C30cycloalkenylene, Ar1; Ar1, Ar2 and Ar3 are for example phenylene, R4, R5, R6, R7 and R8 are for example hydrogen, C3-C30cycloalkyl, C1-C18alkyl, C1-C10haloalkyl, C2-C12alkenyl, C4-C30cycloalkenyl, phenyl-C1C3-alkyl; X- is Formulae (IA), (IB) or (IC); R10 is for example C1-C18alkyl, C1-C10haloalkyl, camphoryl, phenyl-C1-C3alkyl, C3-C30cycloalkyl; and R11, R12, R13, R14 and R15 are for example C1-C10haloalkyl; are useful as polymerizable photolatent acids.

  公式（I）的化合物，其中R1，R2和R3例如是氢，卤素，CN，C1-C18烷基，C1-C10卤代烷基，（CO）R8，（CO）OR4或（CO）NR5R6; Y是O，S或CO; D2，D3和D4例如是直接键，O，S，NR7，CO，O（CO），（CO）O，S（CO），（CO）S，NR7（CO），（CO）NR7，SO，SO2或OSO2，C1-C18烷基，C3-C30环烷基，C2-C12烯基，C4-C30环烯基，Ar1; Ar1，Ar2和Ar3例如是苯基，R4，R5，R6，R7和R8例如是氢，C3-C30环烷基，C1-C18烷基，C1-C10卤代烷基，C2-C12烯基，C4-C30环烯基，苯基-C1C3-烷基; X-是公式（IA），（IB）或（IC）; R10例如是C1-C18烷基，C1-C10卤代烷基，桉叶基，苯基-C1-C3烷基，C3-C30环烷基; R11，R12，R13，R14和R15例如是C1-C10卤代烷基; 作为可聚合光致酸的有用化合物。
• 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS
  申请人：EnVivo Pharmaceuticals, Inc.

  公开号：US20140011808A1

  公开（公告）日：2014-01-09

  1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.

  本文描述了一种抑制磷酸二酯酶10的1,2-二取代杂环化合物。同时还描述了这些化合物的制备过程、制药组合物、制药制剂以及在治疗哺乳动物（包括人类）的中枢神经系统（CNS）疾病和其他可能影响CNS功能的疾病中的制药用途。这些疾病包括神经系统、神经退行性和精神障碍，包括但不限于与认知缺陷或精神分裂症状相关的疾病。
• Ink composition
  申请人：ADGER KOGYO CO., LTD.

  公开号：EP0393901A1

  公开（公告）日：1990-10-24

  A substantially colorless, transparent ink composition which affords erasable, white ink images includes an organic solvent, an organic substance which is dissolved in the organic solvent, which has a molecular weight of less than 1,000 and which is a white or colorless solid at room temperature, and a polymer which is dissolved in the organic solvent and which has a molecular weight of at least 10,000.

  一种基本无色、透明的墨水组合物，可提供可擦除的白色墨水图像，它包括一种有机溶剂、一种溶解在有机溶剂中、分子量小于 1,000 且在室温下为白色或无色固体的有机物，以及一种溶解在有机溶剂中、分子量至少为 10,000 的聚合物。
• Photoisomerization of 4-hydroxypyrylium cations in concentrated sulfuric acid
  作者：James W. Pavlik、Arthur D. Patten、David R. Bolin、Kenneth C. Bradford、Edward L. Clennan

  DOI：10.1021/jo00197a040

  日期：1984.11